KPMG in Precision Medicine

Strategy | Deals | Operations

Alasdair Milton, PhD

Alasdair Milton, PhD

Managing Director, Healthcare and Life Sciences Strategy, KPMG US

+1 617-988-5419

Puja Ghelani

Puja Ghelani

Director, Healthcare and Life Sciences Strategy, KPMG US

+1 918-845-2389

Kristin C. Pothier

Kristin C. Pothier

Global & National, HCLS Deal Advisory & Strategy Leader, KPMG US

+1 617 549 2779

Varun Renjen, MD

Varun Renjen, MD

Managing Director, Life Sciences Deal Advisory and Strategy, KPMG US

+1 973-467-9650


 


The KPMG Precision Medicine practice is a leader in innovation across all therapeutic areas, in markets around the world. Our comprehensive offerings range from strategic front-end ideation and planning, to commercial, financial, and operational due diligence, and continuing through integration and separation. Our approach is fueled by proprietary clinical and lab data which is unparalleled in the market. Click to see more examples of the transformative work we are doing in strategydeals and operations for all stakeholders in the Precision Medicine ecosystem.

See us in action


Watch our Precision Medicine leaders talk about the practice and how KPMG is supporting our clients in their deals, and shaping their strategic direction and operations within this innovative industry.


 

Latest insights

Latest Conference Attendance


Click on the video to watch our global HCLS Deal Advisory and Strategy leader Kristin Pothier at the 2022 Milken Institute Global Conference as she leads a panel discussion on Cures On The Horizon

 



KPMG’s proprietary Precision Medicine Insight database is used to supplement all of our strategy and deals work in the Precision Medicine space worldwide. Survey data is collected annually from molecular pathologists, anatomical pathologists and oncologists in 13 markets, across 4 tumor types - Non-Small Cell Lung Cancer (NSCLC), Breast Cancer, Colorectal Cancer, and Non-Hodgkins Lymphoma (NHL) – and supplemented by deep 1-1 qualitative conversations to gain additional insights into how these key stakeholders view the evolution of the testing landscape and overall Precision Medicine market in the next 5 years.

To understand more about our Precision Medicine Insight database, please contact us.
 


Market Data on 13 Countries Around the World

     
     

Brazil

Canada

China

France

   
 

Germany

India

   

Italy

Japan

Mexico

     

S. Korea

Spain

UK

US


Example Oncologist Question

Oncologists expect the rapid uptake of liquid biopsy for patient monitoring in the next 5 years if technical hurdles are overcome and sufficient evidence is generated. Data from 4 of the 13 countries below. To understand more about trends across all markets, please contact us.


Number of patients per 100 new cancer patients treated where liquid biopsy tests are ordered for monitoring / progression purposes, today and in 5 years (n = 548)1

Notes: (1) Data may disproportionately represent HCPs at larger AMCs and national cancer centers with better funding/access and treat patients of higher socioeconomic status.

 

Example Pathologist Question

Pathologists expect the use of IVD NGS kits to grow rapidly, but this is not a uniform trend across all markets. Data from 4 of the 13 countries below. To understand more about trends across all markets, please contact us.


Number of NGS tests performed using IVD designated kits per 100 NGS tests performed on clinical cancer samples, today and in 5 years (n = 334)



Precision Medicine is a rapidly evolving market, with technologies such as liquid biopsy, gene therapy, and spatial omic imaging set to change treatment paradigms and improve clinical outcomes for patients. However, this complexity offers unique challenges for our clients, as they grapple with the impact Precision Medicine will have across their business - from R&D to supply chain, through to commercialization, and also as they seek to acquire new technologies through licensing or acquisition. Our industry depth, decades long experience, and local market knowledge means we deliver the critical insights needed to inform the key strategic decisions our clients must take to be market leaders in Precision Medicine.

Latest Conference Attendance

Cures on Horizon

People are often hesitant in using the word “cure” in the biotech sector. Watch why KPMG is interested in “cures”, and what are the upcoming opportunities and challenges

  

Team & Contacts

Kristin C. Pothier

Kristin C. Pothier

Global & National, HCLS Deal Advisory & Strategy Leader, KPMG US

+1 617 549 2779
Alasdair Milton, PhD

Alasdair Milton, PhD

Managing Director, Healthcare and Life Sciences Strategy, KPMG US

+1 617-988-5419
Varun Renjen, MD

Varun Renjen, MD

Managing Director, Life Sciences Deal Advisory and Strategy, KPMG US

+1 973-467-9650
Puja Ghelani

Puja Ghelani

Director, Healthcare and Life Sciences Strategy, KPMG US

+1 918-845-2389